With a large number of mid-sized and large-cap med-tech companies outperforming the market over the last three months, it's fair to ask how much of Boston Scientific's (BSX) performance is based on real conviction that the company has turned the corner and how much is based on a sector-wide and market-wide melt-up. Fourth-quarter earnings and management guidance give cause for optimism that Boston Scientific is finally moving past its problems, but investors should not forget the difficulties that come with trying to play catch-up in a fiercely competitive market.
Solid Signs Of Progress In Q4
Boston Scientific has been talking turnaround for a long time now, but fourth-quarter results include actual signs of progress along those...
Only subscribers can access this article, which is part of the PRO research library covering 3,611 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: